Efficacy of Oral Dydrogesterone in Improving Neonatal Birth Weight Outcomes in Idiopathic Intrauterine Growth Restriction: A Prospective Observational Study.

Cureus · 2025 · PMC12447364 · PMID 40978952

Europe PMC DOI

hedged sentences

0.0010

closest p · 0.0× alpha

0.0740

boldest claim

The sentences

highly significantp<0.001actually significant

The overall analysis revealed statistically significant improvement in mean neonatal birth weight in the dydrogesterone group (2.10±0.19 kg, range 1.7-2.5 kg) compared to conventional treatment (1.60±0.22 kg, range 1.2-2.0 kg) with a highly significant statistical difference (t=8.162, p<0.001).

also in 132,142 other papers

did not reach statistical significancep=0.074so close (0.05 < p ≤ 0.1)

Participants receiving dydrogesterone at earlier gestational ages (28-31 weeks, n=13) demonstrated superior birth weight outcomes (2.16±0.16 kg) compared to those initiating treatment at 32-34 weeks (2.02±0.21 kg, n=10), though the difference approached but did not reach statistical significance (t=1.871, p=0.074).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.